Annual report
6095.TEDINET S100UY8M
Period2023-10-01 → 2024-09-30
Filed2024-12-18
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 152
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥14.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥14.5bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥8.5bn | 2021-10-01 → 2022-09-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.4bn | 2020-10-01 → 2021-09-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.3bn | 2019-10-01 → 2020-09-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥1.1bn | 2022-10-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.1bn | 2021-10-01 → 2022-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2020-10-01 → 2021-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2019-10-01 → 2020-09-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.4bn | 2023-10-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.0bn | 2022-10-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥618m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥812m | 2021-10-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.3bn | 2020-10-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥726m | 2019-10-01 → 2020-09-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.5bn | 2023-10-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥638m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥15.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥15.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥9.4bn | at 2022-09-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.5bn | at 2021-09-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥7.1bn | at 2020-09-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.1bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥6.6bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥9.5bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2022-09-30d | Cons. | Net assets |
| Net assets / equity | ¥7.0bn | at 2021-09-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥5.6bn | at 2020-09-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.4bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.1bn | at 2022-09-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.7bn | at 2021-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.7bn | at 2020-09-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥600m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥853m | 2021-10-01 → 2022-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥930m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.0bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥423m | 2021-10-01 → 2022-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥345m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥469m | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.7bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥7m | 2021-10-01 → 2022-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥15m | 2020-10-01 → 2021-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2019-10-01 → 2020-09-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥68.26 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.33 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.62 | 2021-10-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.07 | 2020-10-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.03 | 2019-10-01 → 2020-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.99 | 2022-10-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥35.78 | 2021-10-01 → 2022-09-30d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.25 | 2020-10-01 → 2021-09-30d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥32.67 | 2019-10-01 → 2020-09-30d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥434.74 | at 2024-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥382.1 | at 2023-09-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥350.71 | at 2022-09-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥310.47 | at 2021-09-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥248.8 | at 2020-09-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 60.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.1% | at 2022-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.5% | at 2021-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.0% | at 2020-09-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 16.7% | 2023-10-01 → 2024-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2022-10-01 → 2023-09-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.4% | 2021-10-01 → 2022-09-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 21.5% | 2020-10-01 → 2021-09-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.9% | 2019-10-01 → 2020-09-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 489 | at 2024-09-30 | Cons. | Number of employees |
| Employees | 611 | at 2023-09-30 | Cons. | Number of employees |
| Employees | 373 | at 2022-09-30d | Cons. | Number of employees |
| Employees | 272 | at 2021-09-30d | Cons. | Number of employees |
| Employees | 225 | at 2020-09-30d | Cons. | Number of employees |
| Revenue | ¥4.3bn | 2023-10-01 → 2024-09-30 | Standalone | Net sales |
| Revenue | ¥4.3bn | 2022-10-01 → 2023-09-30 | Standalone | Net sales |
| Revenue | ¥4.7bn | 2021-10-01 → 2022-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.4bn | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.2bn | 2019-10-01 → 2020-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥311m | 2023-10-01 → 2024-09-30 | Standalone | Operating income |
| Operating income | ¥448m | 2022-10-01 → 2023-09-30 | Standalone | Operating income |
| Ordinary income | ¥291m | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥471m | 2022-10-01 → 2023-09-30 | Standalone | Ordinary income |
| Ordinary income | ¥878m | 2021-10-01 → 2022-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥805m | 2019-10-01 → 2020-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥73m | 2023-10-01 → 2024-09-30 | Standalone | Income before income taxes |
| Profit before tax | ¥344m | 2022-10-01 → 2023-09-30 | Standalone | Income before income taxes |
| Net income | −¥35m | 2023-10-01 → 2024-09-30 | Standalone | Profit loss |
| Net income | ¥218m | 2022-10-01 → 2023-09-30 | Standalone | Profit loss |
| Net income | ¥648m | 2021-10-01 → 2022-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.1bn | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥579m | 2019-10-01 → 2020-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥11.0bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥11.7bn | at 2023-09-30 | Standalone | Assets |
| Total assets | ¥7.7bn | at 2022-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.1bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.0bn | at 2020-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.9bn | at 2024-09-30 | Standalone | Liabilities |
| Total liabilities | ¥4.5bn | at 2023-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥7.1bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥7.2bn | at 2023-09-30 | Standalone | Net assets |
| Net assets / equity | ¥6.9bn | at 2022-09-30d | Standalone | Net assets |
| Net assets / equity | ¥6.1bn | at 2021-09-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥5.0bn | at 2020-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2024-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.5bn | at 2023-09-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥-1.61 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.98 | 2022-10-01 → 2023-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.03 | 2021-10-01 → 2022-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥49.7 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.92 | 2019-10-01 → 2020-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥9.86 | 2022-10-01 → 2023-09-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥28.56 | 2021-10-01 → 2022-09-30d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.54 | 2020-10-01 → 2021-09-30d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.04 | 2019-10-01 → 2020-09-30d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥4.5 | 2023-10-01 → 2024-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥4.5 | 2022-10-01 → 2023-09-30 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥324.72 | at 2024-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥330.22 | at 2023-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥317.15 | at 2022-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥284.02 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥232.58 | at 2020-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 64.1% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.4% | at 2023-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.0% | at 2022-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.7% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2020-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.1% | 2022-10-01 → 2023-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.0% | 2021-10-01 → 2022-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 19.2% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.4% | 2019-10-01 → 2020-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 21,986,410 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,953,590 | at 2023-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,622,580 | at 2022-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,574,190 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,473,100 | at 2020-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 195 | at 2024-09-30 | Standalone | Number of employees |
| Employees | 210 | at 2023-09-30 | Standalone | Number of employees |
| Employees | 203 | at 2022-09-30d | Standalone | Number of employees |
| Employees | 151 | at 2021-09-30d | Standalone | Number of employees |
| Employees | 116 | at 2020-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 67
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-10-01 → 2024-09-30 | ¥144m |
| Reconciling Itemsreconciling | depreciation | 2023-10-01 → 2024-09-30 | ¥62m |
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2024-09-30 | −¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2024-09-30 | −¥2m |
| Reconciling Itemsreconciling | segment assets | at 2024-09-30 | ¥8.6bn |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-09-30 | −¥1.4bn |
| Collective Intelligence Platformreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥76m |
| Collective Intelligence Platformreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥252m |
| Collective Intelligence Platformreportable segment | employees | at 2024-09-30 | 391 pure |
| Collective Intelligence Platformreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥12.3bn |
| Collective Intelligence Platformreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥12.3bn |
| Collective Intelligence Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-09-30 | ¥1m |
| Collective Intelligence Platformreportable segment | segment assets | at 2024-09-30 | ¥6.9bn |
| Collective Intelligence Platformreportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥2.6bn |
| Medical Institution Support Platformreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥1m |
| Medical Institution Support Platformreportable segment | employees | at 2024-09-30 | 36 pure |
| Medical Institution Support Platformreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥456m |
| Medical Institution Support Platformreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥456m |
| Medical Institution Support Platformreportable segment | segment assets | at 2024-09-30 | ¥36m |
| Medical Institution Support Platformreportable segment | segment profit | 2023-10-01 → 2024-09-30 | −¥182m |
| Preventive Healthcare Platformreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥36m |
| Preventive Healthcare Platformreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥23m |
| Preventive Healthcare Platformreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥2.2bn |
| Preventive Healthcare Platformreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥2.2bn |
| Preventive Healthcare Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-09-30 | ¥918,000 |
| Preventive Healthcare Platformreportable segment | segment assets | at 2024-09-30 | ¥43m |
| Preventive Healthcare Platformreportable segment | segment profit | 2023-10-01 → 2024-09-30 | ¥284m |
| —segment total | capex | 2023-10-01 → 2024-09-30 | ¥111m |
| —segment total | depreciation | 2023-10-01 → 2024-09-30 | ¥277m |
| —segment total | revenue | 2023-10-01 → 2024-09-30 | ¥15.0bn |
| —segment total | revenue external | 2023-10-01 → 2024-09-30 | ¥14.9bn |
| —segment total | revenue intersegment | 2023-10-01 → 2024-09-30 | ¥2m |
| —segment total | segment assets | at 2024-09-30 | ¥6.9bn |
| —segment total | segment profit | 2023-10-01 → 2024-09-30 | ¥2.7bn |
| Reconciling Itemsreconciling | capex | 2022-10-01 → 2023-09-30 | ¥32m |
| Reconciling Itemsreconciling | depreciation | 2022-10-01 → 2023-09-30 | ¥72m |
| Reconciling Itemsreconciling | revenue | 2022-10-01 → 2023-09-30 | −¥7m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-10-01 → 2023-09-30 | −¥7m |
| Reconciling Itemsreconciling | segment assets | at 2023-09-30 | ¥6.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-09-30 | −¥1.4bn |
| Collective Intelligence Platformreportable segment | capex | 2022-10-01 → 2023-09-30 | ¥60m |
| Collective Intelligence Platformreportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥410m |
| Collective Intelligence Platformreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥11.8bn |
| Collective Intelligence Platformreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥11.8bn |
| Collective Intelligence Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-09-30 | ¥4m |
| Collective Intelligence Platformreportable segment | segment assets | at 2023-09-30 | ¥7.8bn |
| Collective Intelligence Platformreportable segment | segment profit | 2022-10-01 → 2023-09-30 | ¥2.4bn |
| Medical Institution Support Platformreportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥1m |
| Medical Institution Support Platformreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥502m |
| Medical Institution Support Platformreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥499m |
| Medical Institution Support Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-09-30 | ¥3m |
| Medical Institution Support Platformreportable segment | segment assets | at 2023-09-30 | ¥392m |
| Medical Institution Support Platformreportable segment | segment profit | 2022-10-01 → 2023-09-30 | −¥92m |
| Preventive Healthcare Platformreportable segment | capex | 2022-10-01 → 2023-09-30 | ¥17m |
| Preventive Healthcare Platformreportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥19m |
| Preventive Healthcare Platformreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥2.2bn |
| Preventive Healthcare Platformreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥2.2bn |
| Preventive Healthcare Platformreportable segment | revenue intersegment | 2022-10-01 → 2023-09-30 | ¥653,000 |
| Preventive Healthcare Platformreportable segment | segment assets | at 2023-09-30 | ¥452m |
| Preventive Healthcare Platformreportable segment | segment profit | 2022-10-01 → 2023-09-30 | ¥172m |
| —segment total | capex | 2022-10-01 → 2023-09-30 | ¥77m |
| —segment total | depreciation | 2022-10-01 → 2023-09-30 | ¥430m |
| —segment total | revenue | 2022-10-01 → 2023-09-30 | ¥14.5bn |
| —segment total | revenue external | 2022-10-01 → 2023-09-30 | ¥14.5bn |
| —segment total | revenue intersegment | 2022-10-01 → 2023-09-30 | ¥7m |
| —segment total | segment assets | at 2023-09-30 | ¥8.6bn |
| —segment total | segment profit | 2022-10-01 → 2023-09-30 | ¥2.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,414
| Item | Context | Value | Unit |
|---|---|---|---|
| Recruiting expenses sga | CurrentYearDuration_NonConsolidatedMember | 53865000 | JPY |
| Depreciation sga | Prior1YearDuration_NonConsolidatedMember | 46304000 | JPY |
| Depreciation sga | CurrentYearDuration_NonConsolidatedMember | 39915000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-12-18 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第20期（自 2023年10月１日 至 2024年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)メドピア株式会社 | |
| Company name in english cover page | FilingDateInstant | MedPeer, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役 兼 執行役員社長CEO 後藤 直樹 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区築地一丁目13番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-4405-4905 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役 兼 執行役員CFO 平林 利夫 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区築地一丁目13番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-4405-4905 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役 兼 執行役員CFO 平林 利夫 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E30650 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 60950 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)メドピア株式会社 | |
| Filer name in english | FilingDateInstant | MedPeer, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2023-10-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2024-09-30 | |
| Previous fiscal year start date | FilingDateInstant | 2022-10-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-09-30 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |